|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
1994
|
|
gptkbp:ATCCode
|
A10BA02
|
|
gptkbp:bioavailability
|
50-60%
|
|
gptkbp:brand
|
gptkb:Riomet
gptkb:Fortamet
gptkb:Glucophage
gptkb:Glumetza
|
|
gptkbp:CASNumber
|
657-24-9
|
|
gptkbp:category
|
antidiabetic agent
biguanide
|
|
gptkbp:contraindication
|
metabolic acidosis
renal impairment
|
|
gptkbp:discoveredBy
|
gptkb:Jean_Sterne
|
|
gptkbp:eliminationHalfLife
|
4-8.7 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:firstMarketedYear
|
1957
|
|
gptkbp:form
|
500 mg
C4H11N5
1000 mg
850 mg
|
|
gptkbp:hasInChIKey
|
gptkb:XZWYZXLIPXDOLR-UHFFFAOYSA-N
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB00318
|
|
gptkbp:indication
|
gptkb:type_2_diabetes_mellitus
|
|
gptkbp:interactsWith
|
gptkb:beer
cimetidine
furosemide
|
|
gptkbp:isOnWHOList
|
true
|
|
gptkbp:KEGGID
|
gptkb:D01841
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:France
|
|
gptkbp:maximumDosage
|
2550 mg/day
|
|
gptkbp:mechanismOfAction
|
decreases hepatic glucose production
increases insulin sensitivity
|
|
gptkbp:metabolism
|
not metabolized
|
|
gptkbp:molecularWeight
|
129.164
|
|
gptkbp:name
|
gptkb:Metformin
|
|
gptkbp:origin
|
synthetic
|
|
gptkbp:pharmacodynamics
|
lowers blood glucose without causing hypoglycemia
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
negligible
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1431
gptkb:DB00318
4091
3949
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gastrointestinal upset
lactic acidosis
|
|
gptkbp:smiles
|
CN(C)C(=N)N=C(N)N
|
|
gptkbp:synonym
|
1,1-dimethylbiguanide
dimethylbiguanide
|
|
gptkbp:target
|
gptkb:AMP-activated_protein_kinase
|
|
gptkbp:toxicity
|
lactic acidosis risk
|
|
gptkbp:UNII
|
9100L32L2N
|
|
gptkbp:bfsParent
|
gptkb:Codeine
gptkb:codeine
|
|
gptkbp:bfsLayer
|
6
|